Page last updated: 2024-10-24
celecoxib and Lymphangiomyomatosis
celecoxib has been researched along with Lymphangiomyomatosis in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| El-Chemaly, S | 1 |
| Taveira-DaSilva, A | 1 |
| Bagwe, S | 1 |
| Klonowska, K | 1 |
| Machado, T | 1 |
| Lamattina, AM | 1 |
| Goldberg, HJ | 1 |
| Jones, AM | 1 |
| Julien-Williams, P | 1 |
| Maurer, R | 1 |
| Rosas, IO | 1 |
| Henske, EP | 1 |
| Moss, J | 1 |
| Kwiatkowski, DJ | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC[NCT02484664] | Phase 2 | 12 participants (Actual) | Interventional | 2016-06-15 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Angiomyolipoma Size Measured Volumetrically on MRI
We are reporting the number of participants in this trial who had angiomyolipoma either at the beginning or end of the study. (NCT02484664)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|
| Celecoxib | 3 |
FEV1
Forced expiratory volume in 1 second (NCT02484664)
Timeframe: 1 year
| Intervention | ml (Least Squares Mean) |
|---|
| Celecoxib | 2583 |
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Number of Participants with Adverse Events as a Measure of Safety and Tolerability in LAM patients (NCT02484664)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|
| Celecoxib | 11 |
St. George's Respiratory Questionnaire
"St. George's Respiratory Questionnaire is a commonly used questionnaire to assess the respiratory function of an individual.~The minimum and maximyum socres on this Questionnaire are: 0 and 100. A higher score shows more limitations, so a lower score is better in terms of respiratory function.~There are no subscales. Below we are providing mean scores for all 9 participants in this trial." (NCT02484664)
Timeframe: 1 year
| Intervention | score on a scale (Least Squares Mean) |
|---|
| Celecoxib | 20.2 |
VEGF-D Serum Levels
VEGF-D serum levels (NCT02484664)
Timeframe: 6 months
| Intervention | pg/mL (Median) |
|---|
| Celecoxib | 656 |
Trials
1 trial available for celecoxib and Lymphangiomyomatosis